| Year |
Citation |
Score |
| 2023 |
Maziarz RT, Devine S, Garrison LP, Agodoa I, Badaracco J, Gitlin M, Perales MA. Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient. Transplantation and Cellular Therapy. PMID 37364775 DOI: 10.1016/j.jtct.2023.06.013 |
0.312 |
|
| 2023 |
Babigumira JB, Karichu JK, Clark S, Cheng MM, Garrison LP, Maniecki MB, Hamid SS. Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison. Bmj Open. 13: e066770. PMID 37142306 DOI: 10.1136/bmjopen-2022-066770 |
0.574 |
|
| 2022 |
Postma MJ, Noone D, Rozenbaum MH, Carter JA, Botteman MF, Fenwick E, Garrison LP. Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose? Orphanet Journal of Rare Diseases. 17: 157. PMID 35382853 DOI: 10.1186/s13023-022-02283-z |
0.313 |
|
| 2021 |
Thornburg CD, Adamski K, Cook K, Vembusubramanian M, Sendhil SR, Hinds D, Chen E, Sammon J, Solari P, Garrison LP, Croteau SE. Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. Journal of Managed Care & Specialty Pharmacy. 1-12. PMID 34958235 DOI: 10.18553/jmcp.2021.21368 |
0.326 |
|
| 2021 |
Dabbous M, Toumi M, Simoens S, Wasem J, Saal G, Wang Y, Osuna JLH, François C, Annemans L, Graf von der Schulenburg JM, Sola-Morales O, Malone D, Garrison LP. Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments. Health Policy (Amsterdam, Netherlands). PMID 34863529 DOI: 10.1016/j.healthpol.2021.11.005 |
0.313 |
|
| 2021 |
Garrison LP, Jiao B, Dabbous O. Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies. Journal of Managed Care & Specialty Pharmacy. 27: 674-681. PMID 33908277 DOI: 10.18553/jmcp.2021.27.5.674 |
0.304 |
|
| 2021 |
Zamora B, Garrison LP, Unuigbe A, Towse A. Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting? Cost Effectiveness and Resource Allocation : C/E. 19: 13. PMID 33648523 DOI: 10.1186/s12962-021-00266-8 |
0.356 |
|
| 2020 |
Coyle D, Durand-Zaleski I, Farrington J, Garrison L, Graf von der Schulenburg JM, Greiner W, Longworth L, Meunier A, Moutié AS, Palmer S, Pemberton-Whiteley Z, Ratcliffe M, Shen J, Sproule D, Zhao K, et al. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. PMID 32794011 DOI: 10.1007/S10198-020-01212-W |
0.33 |
|
| 2020 |
Quinn C, Garrison LP, Pownell AK, Atkins MB, de Pouvourville G, Harrington K, Ascierto PA, McEwan P, Wagner S, Borrill J, Wu E. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. Journal For Immunotherapy of Cancer. 8. PMID 32661115 DOI: 10.1136/Jitc-2020-000648 |
0.31 |
|
| 2020 |
Duarte HA, Babigumira JB, Enns EA, Stauffer DC, Shafer RW, Beck IA, Garrison LP, Chung MH, Frenkel LM, Bendavid E. Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women. Eclinicalmedicine. 22: 100355. PMID 32490370 DOI: 10.1016/J.Eclinm.2020.100355 |
0.634 |
|
| 2020 |
Garrison LP, Zamora B, Li M, Towse A. Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support. Journal of Managed Care & Specialty Pharmacy. 26: 400-406. PMID 32223599 DOI: 10.18553/Jmcp.2020.26.4.400 |
0.375 |
|
| 2020 |
Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison LP. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. Journal of Medical Economics. 1. PMID 31971453 DOI: 10.1080/13696998.2020.1721508 |
0.424 |
|
| 2020 |
Khaki AR, Diamantopoulos LN, Zimmerman M, Garrison LP, Grivas P. Assessing the potential cost-effectiveness of the addition of atezolizumab to first-line platinum chemotherapy in advanced urothelial cancer: Implications for value-based pricing. Journal of Clinical Oncology. 38: 5031-5031. DOI: 10.1200/jco.2020.38.15_suppl.5031 |
0.363 |
|
| 2019 |
Garrison LP, Neumann PJ, Willke RJ. Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy. Journal of Managed Care & Specialty Pharmacy. 25: 1185-1192. PMID 31663458 DOI: 10.18553/Jmcp.2019.25.11.1185 |
0.302 |
|
| 2019 |
Yu PP, Eton O, Garrison LP. Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer. Journal For Immunotherapy of Cancer. 7: 235. PMID 31481112 DOI: 10.1186/S40425-019-0707-9 |
0.379 |
|
| 2019 |
Adamson B, Garrison L, Barnabas RV, Carlson JJ, Kublin J, Dimitrov D. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA. Journal of the International Aids Society. 22: e25373. PMID 31402591 DOI: 10.1002/Jia2.25373 |
0.3 |
|
| 2019 |
Dankó D, Blay JY, Garrison LP. Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology. Health Policy (Amsterdam, Netherlands). PMID 31337514 DOI: 10.1016/J.Healthpol.2019.07.009 |
0.312 |
|
| 2019 |
Wurcel V, Cicchetti A, Garrison L, Kip MMA, Koffijberg H, Kolbe A, Leeflang MMG, Merlin T, Mestre-Ferrandiz J, Oortwijn W, Oosterwijk C, Tunis S, Zamora B. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems. Public Health Genomics. 22: 8-15. PMID 31330522 DOI: 10.1159/000501832 |
0.336 |
|
| 2019 |
Li M, Basu A, Bennette C, Veenstra D, Garrison LP. How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 777-784. PMID 31277824 DOI: 10.1016/J.Jval.2019.02.002 |
0.411 |
|
| 2019 |
Garrison LP, Jansen JP, Devlin NJ, Griffin S. Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: S12-S17. PMID 31200801 DOI: 10.1016/J.Jval.2019.04.1915 |
0.405 |
|
| 2019 |
Yeung K, Suh K, Garrison LP, Carlson JJ. Defining and Managing High-Priced Cures: Healthcare Payers' Opinions. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 648-655. PMID 31198181 DOI: 10.1016/J.Jval.2018.11.012 |
0.417 |
|
| 2019 |
Vodicka EL, Chung MH, Zimmermann MR, Kosgei RJ, Lee F, Mugo NR, Okech TC, Sakr SR, Stergachis A, Garrison LP, Babigumira JB. Estimating the costs of HIV clinic integrated versus non-integrated treatment of pre-cancerous cervical lesions and costs of cervical cancer treatment in Kenya. Plos One. 14: e0217331. PMID 31170193 DOI: 10.1371/Journal.Pone.0217331 |
0.646 |
|
| 2019 |
Guzauskas GF, Pollom EL, Stieber VW, Wang BCM, Garrison L. Tumor treating fields and maintenance temozolomide for newly diagnosed glioblastoma: a cost-effectiveness study. Journal of Medical Economics. 1. PMID 31050315 DOI: 10.1080/13696998.2019.1614933 |
0.343 |
|
| 2019 |
Garrison LP, Babigumira J, Tournier C, Goertz HP, Lubinga SJ, Perez EA. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 408-415. PMID 30975391 DOI: 10.1016/J.Jval.2018.11.014 |
0.628 |
|
| 2019 |
Garrison LP, Jackson T, Paul D, Kenston M. Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold. Journal of Managed Care & Specialty Pharmacy. 1-7. PMID 30784347 DOI: 10.18553/Jmcp.2019.18378 |
0.351 |
|
| 2019 |
Adamson B, El-Sadr W, Dimitrov D, Gamble T, Beauchamp G, Carlson JJ, Garrison L, Donnell D. The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 194-202. PMID 30711064 DOI: 10.1016/J.Jval.2018.09.001 |
0.382 |
|
| 2018 |
Mejía A, Gilardino R, Kristensen FB, Garrison LP. Value-Based Pricing in Latin America: How Far Away Are We? Value in Health Regional Issues. 17: 219-223. PMID 30528780 DOI: 10.1016/J.Vhri.2018.09.007 |
0.378 |
|
| 2018 |
Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL. Economic Analysis of Vaccination Programs. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 1133-1149. PMID 30314613 DOI: 10.1016/J.Jval.2018.08.005 |
0.364 |
|
| 2018 |
Garrison LP, Neumann PJ, Willke RJ, Basu A, Danzon PM, Doshi JA, Drummond MF, Lakdawalla DN, Pauly MV, Phelps CE, Ramsey SD, Towse A, Weinstein MC. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 161-165. PMID 29477394 DOI: 10.1016/J.Jval.2017.12.009 |
0.428 |
|
| 2018 |
Willke RJ, Neumann PJ, Garrison LP, Ramsey SD. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 155-160. PMID 29477393 DOI: 10.1016/J.Jval.2017.12.011 |
0.403 |
|
| 2018 |
Lakdawalla DN, Doshi JA, Garrison LP, Phelps CE, Basu A, Danzon PM. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3]. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 131-139. PMID 29477390 DOI: 10.1016/J.Jval.2017.12.007 |
0.383 |
|
| 2018 |
Garrison LP, Pauly MV, Willke RJ, Neumann PJ. An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2]. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 124-130. PMID 29477389 DOI: 10.1016/J.Jval.2017.12.006 |
0.362 |
|
| 2018 |
Neumann PJ, Willke RJ, Garrison LP. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1]. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 119-123. PMID 29477388 DOI: 10.1016/J.Jval.2017.12.012 |
0.336 |
|
| 2018 |
Lubinga S, Babigumira J, Graham S, Mukose A, Garrison L, Basu A. Heterogeneity in Preferences for Medical Male Circumcision Services: A Discrete Choice Experiment Among Uncircumcised Men In Fishing Communities in Uganda Value in Health. 21: S127. DOI: 10.1016/J.Jval.2018.04.961 |
0.513 |
|
| 2017 |
Yenikomshian MA, White AG, Carson ME, Garrison LP, Oderda GM, Biskupiak JE, Hlavacek PR, Roland CL. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients. Journal of Opioid Management. 13: 291-301. PMID 29199395 DOI: 10.5055/Jom.2017.0398 |
0.336 |
|
| 2017 |
Li M, Nyabigambo A, Navvuga P, Nuwamanya E, Nuwasiima A, Kaganda P, Asiimwe FT, Vodicka E, Mugisha NM, Mukose A, Kwesiga DK, Lubinga SJ, Garrison LP, Babigumira JB. Acceptability of cervical cancer screening using visual inspection among women attending a childhood immunization clinic in Uganda. Papillomavirus Research (Amsterdam, Netherlands). 4: 17-21. PMID 29179864 DOI: 10.1016/J.Pvr.2017.06.004 |
0.576 |
|
| 2017 |
Yeung K, Suh K, Basu A, Garrison LP, Bansal A, Carlson JJ. Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs. Journal of Managed Care & Specialty Pharmacy. 23: 1084-1090. PMID 28944726 DOI: 10.18553/Jmcp.2017.23.10.1084 |
0.373 |
|
| 2017 |
Babigumira JB, Sharara FI, Garrison LP. Projecting the potential impact of the Cap-Score™ on clinical pregnancy, live births, and medical costs in couples with unexplained infertility. Journal of Assisted Reproduction and Genetics. PMID 28942518 DOI: 10.1007/S10815-017-1021-4 |
0.654 |
|
| 2017 |
Garrison LP, Towse A. Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics. Journal of Personalized Medicine. 7. PMID 28869571 DOI: 10.3390/Jpm7030010 |
0.353 |
|
| 2017 |
Banerjee S, Garrison LP, Danel A, Ochoa Gautier JB, Flum DR. Effects of arginine-based immunonutrition on inpatient total costs and hospitalization outcomes for patients undergoing colorectal surgery. Nutrition (Burbank, Los Angeles County, Calif.). PMID 28734748 DOI: 10.1016/J.Nut.2017.06.002 |
0.359 |
|
| 2017 |
Zimmermann MR, Vodicka E, Babigumira JB, Okech T, Mugo N, Sakr S, Garrison LP, Chung MH. Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in Kenya. Cost Effectiveness and Resource Allocation : C/E. 15: 13. PMID 28725164 DOI: 10.1186/S12962-017-0075-6 |
0.643 |
|
| 2017 |
Banerjee S, Garrison LP, Flum DR, Arterburn DE. Cost and Health Care Utilization Implications of Bariatric Surgery Versus Intensive Lifestyle and Medical Intervention for Type 2 Diabetes. Obesity (Silver Spring, Md.). PMID 28722299 DOI: 10.1002/Oby.21927 |
0.333 |
|
| 2017 |
Adamson BJS, Carlson JJ, Kublin JG, Garrison LP. The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States. Vaccines. 5. PMID 28538691 DOI: 10.3390/Vaccines5020013 |
0.357 |
|
| 2017 |
Garrison LP, Kamal-Bahl S, Towse A. Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 20: 213-216. PMID 28237197 DOI: 10.1016/J.Jval.2016.12.005 |
0.428 |
|
| 2017 |
Vodicka EL, Babigumira JB, Mann MR, Kosgei RJ, Lee F, Mugo NR, Okech TC, Sakr SR, Garrison LP, Chung MH. Costs of integrating cervical cancer screening at an HIV clinic in Kenya. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 136: 220-228. PMID 28099724 DOI: 10.1002/Ijgo.12025 |
0.637 |
|
| 2017 |
Babigumira JB, Li M, Boudreau DM, Best JH, Garrison LP. Estimating the Cost of Illness of Giant Cell Arteritis in the United States. Rheumatology and Therapy. PMID 28084585 DOI: 10.1007/s40744-017-0052-8 |
0.637 |
|
| 2017 |
Kaufman HL, Atkins MB, Dicker AP, Jim HS, Garrison LP, Herbst RS, McGivney WT, Silverstein S, Wigginton JM, Yu PP. The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting Journal For Immunotherapy of Cancer. 5. DOI: 10.1186/S40425-017-0241-6 |
0.329 |
|
| 2017 |
Towse A, Garrison L. Value assessment in precision cancer medicine Journal of Cancer Policy. 11: 48-53. DOI: 10.1016/J.Jcpo.2016.09.003 |
0.349 |
|
| 2016 |
Garrison LP, Zimmermann MR, Young CH, Crittendon J, Généreux P. Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-up. Cardiovascular Revascularization Medicine : Including Molecular Interventions. PMID 28017543 DOI: 10.1016/J.Carrev.2016.12.005 |
0.304 |
|
| 2016 |
Chen Y, Guzauskas GF, Gu C, Wang BC, Furnback WE, Xie G, Dong P, Garrison LP. Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value. Journal of Personalized Medicine. 6. PMID 27827859 DOI: 10.3390/Jpm6040020 |
0.411 |
|
| 2016 |
Garrison LP. Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?-An Overview. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 19: 512-5. PMID 27565265 DOI: 10.1016/J.Jval.2016.04.018 |
0.407 |
|
| 2016 |
Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, Garrison LP, Stergachis A. Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis. Drug Safety. PMID 27314405 DOI: 10.1007/S40264-016-0432-Y |
0.657 |
|
| 2016 |
Malone DC, Berg NS, Claxton K, Garrison LP, IJzerman M, Marsh K, Neumann PJ, Sculpher M, Towse A, Uyl-de Groot C, Weinstein MC. International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27298420 DOI: 10.1200/Jco.2015.64.4328 |
0.382 |
|
| 2016 |
Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Baeten JM, Babigumira JB, Garrison LP, Stergachis A. Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia. Pharmacoepidemiology and Drug Safety. PMID 27134056 DOI: 10.1002/Pds.4022 |
0.592 |
|
| 2016 |
Babigumira JB, Jenny AM, Bartlein R, Stergachis A, Garrison LP. Health technology assessment in low- and middle-income countries: A landscape assessment Journal of Pharmaceutical Health Services Research. DOI: 10.1111/Jphs.12120 |
0.609 |
|
| 2016 |
Babigumira J, Sharara F, Garrison L. Potential impact of the Cap-Score test™ on clinical pregnancy and medical costs in couples with unexplained infertility Fertility and Sterility. 106: e299. DOI: 10.1016/J.Fertnstert.2016.07.848 |
0.636 |
|
| 2015 |
Chambers J, Généreux P, Lee A, Lewin J, Young C, Crittendon J, Mann M, Garrison LP. The potential cost-effectiveness of the Diamondback 360® Coronary Orbital Atherectomy System for treating de novo, severely calcified coronary lesions: an economic modeling approach. Therapeutic Advances in Cardiovascular Disease. PMID 26702147 DOI: 10.1177/1753944715622145 |
0.31 |
|
| 2015 |
Garrison LP, Lewin J, Young CH, Généreux P, Crittendon J, Mann MR, Brindis RG. The clinical and cost burden of coronary calcification in a Medicare cohort: An economic model to address under-reporting and misclassification. Cardiovascular Revascularization Medicine : Including Molecular Interventions. PMID 26361178 DOI: 10.1016/J.Carrev.2015.08.002 |
0.307 |
|
| 2015 |
Canestaro WJ, Pritchard DE, Garrison LP, Dubois R, Veenstra DL. Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT). Journal of Managed Care & Specialty Pharmacy. 21: 700-12. PMID 26233542 DOI: 10.18553/Jmcp.2015.21.8.700 |
0.314 |
|
| 2015 |
Garrison LP, Babigumira JB, Masaquel A, Wang BC, Lalla D, Brammer M. The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: 541-6. PMID 26091608 DOI: 10.1016/J.Jval.2015.01.012 |
0.613 |
|
| 2015 |
Wang B, Roth JA, Nguyen H, Felber E, Furnback W, Garrison LP. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States. Plos One. 10: e0121915. PMID 25849542 DOI: 10.1371/Journal.Pone.0121915 |
0.344 |
|
| 2015 |
Sullivan SD, Yeung K, Vogeler C, Ramsey SD, Wong E, Murphy CO, Danielson D, Veenstra DL, Garrison LP, Burke W, Watkins JB. Design, implementation, and first-year outcomes of a value-based drug formulary. Journal of Managed Care & Specialty Pharmacy. 21: 269-75. PMID 25803760 DOI: 10.18553/Jmcp.2015.21.4.269 |
0.348 |
|
| 2015 |
Perrin A, Sherman S, Pal S, Chua A, Gorritz M, Liu Z, Wang X, Culver K, Casciano R, Garrison LP. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. Journal of Medical Economics. 18: 200-9. PMID 25422989 DOI: 10.3111/13696998.2014.985789 |
0.319 |
|
| 2015 |
Babigumira J, Li M, Boudreau D, Best J, Garrison L. THU0347 Estimating the Cost of Illness of Giant Cell Arteritis Annals of the Rheumatic Diseases. 74: 321.1-321. DOI: 10.1136/Annrheumdis-2015-Eular.5013 |
0.648 |
|
| 2015 |
Babigumira J, Li M, Boudreau D, Best J, Garrison L. Estimating The Cost Of Illness Of Giant Cell Arteritis Value in Health. 18: A138. DOI: 10.1016/J.Jval.2015.03.805 |
0.614 |
|
| 2015 |
Garrison LP, Lewin J, Young CH, Généreux P, Crittendon J, Mann MR, Brindis RG. CRT-171 The Clinical and Cost Burden of Coronary Calcification: An Economic Model to Address Under-reporting and Misclassification Jacc: Cardiovascular Interventions. 8: S30. DOI: 10.1016/J.Jcin.2014.12.224 |
0.352 |
|
| 2014 |
Agapova M, Devine EB, Bresnahan BW, Higashi MK, Garrison LP. Applying quantitative benefit-risk analysis to aid regulatory decision making in diagnostic imaging: methods, challenges, and opportunities. Academic Radiology. 21: 1138-43. PMID 25107866 DOI: 10.1016/J.Acra.2014.05.006 |
0.333 |
|
| 2014 |
Akhavan A, Shnorhavorian M, Garrison LP, Merguerian PA. Resource utilization and costs associated with the diagnostic evaluation of nonrefluxing primary hydronephrosis in infants. The Journal of Urology. 192: 919-24. PMID 24704116 DOI: 10.1016/J.Juro.2014.03.110 |
0.382 |
|
| 2014 |
Babigumira JB, Stergachis A, Choi HL, Dodoo A, Nwokike J, Garrison LP. A framework for assessing the economic value of pharmacovigilance in low- and middle-income countries. Drug Safety. 37: 127-34. PMID 24550105 DOI: 10.1007/S40264-014-0143-1 |
0.672 |
|
| 2014 |
Wang BC, Wong ES, Alfonso-Cristancho R, He H, Flum DR, Arterburn DE, Garrison LP, Sullivan SD. Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. 15: 253-63. PMID 23526126 DOI: 10.1007/S10198-013-0472-5 |
0.312 |
|
| 2014 |
Babigumira JB, Santos E, Antao VP, Wang B, Portera CC, Kamath T, Garrison LP. Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer. Journal of Clinical Oncology. 32: 642-642. DOI: 10.1200/Jco.2014.32.15_Suppl.642 |
0.63 |
|
| 2014 |
Mann M, Babigumira J, Garrison L, Chung M. Assessing the Potential Cost-Effectiveness of Alternative Methods to Screen for Cervical Cancer Among HIV-Positive Women in Kenya Value in Health. 17: A82. DOI: 10.1016/J.Jval.2014.03.481 |
0.602 |
|
| 2013 |
Towse A, Ossa D, Veenstra D, Carlson J, Garrison L. Understanding the economic value of molecular diagnostic tests: case studies and lessons learned. Journal of Personalized Medicine. 3: 288-305. PMID 25562729 DOI: 10.3390/Jpm3040288 |
0.388 |
|
| 2013 |
Towse A, Garrison LP. Economic incentives for evidence generation: promoting an efficient path to personalized medicine. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 16: S39-43. PMID 24034311 DOI: 10.1016/J.Jval.2013.06.003 |
0.378 |
|
| 2013 |
Garrison LP, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JL, Siviero P, Sleeper M. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 16: 703-19. PMID 23947963 DOI: 10.1016/J.Jval.2013.04.011 |
0.42 |
|
| 2013 |
Garrison LP, Lalla D, Brammer M, Babigumira JB, Wang B, Perez EA. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status. Cancer. 119: 3113-22. PMID 23775560 DOI: 10.1002/cncr.28196 |
0.632 |
|
| 2013 |
Campbell JD, Zerzan J, Garrison LP, Libby AM. Comparative-effectiveness research to aid population decision making by relating clinical outcomes and quality-adjusted life years. Clinical Therapeutics. 35: 364-70. PMID 23477685 DOI: 10.1016/J.Clinthera.2013.02.011 |
0.304 |
|
| 2013 |
Garrison LP, Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, van de Velde H, Corzo D, Duh MS. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. The Oncologist. 18: 27-36. PMID 23299777 DOI: 10.1634/Theoncologist.2011-0380 |
0.424 |
|
| 2013 |
Barzey V, Atkins MB, Garrison LP, Asukai Y, Kotapati S, Penrod JR. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. Journal of Medical Economics. 16: 202-12. PMID 23057750 DOI: 10.3111/13696998.2012.739226 |
0.413 |
|
| 2013 |
Garau M, Towse A, Garrison L, Housman L, Ossa D. Can and should value-based pricing be applied to molecular diagnostics? Personalized Medicine. 10: 61-72. DOI: 10.2217/Pme.12.99 |
0.372 |
|
| 2013 |
Wang BCM, Furnback WE, Ney JP, Garrison LP, Fang C. THU0511 Estimating the Burden of Illness of Fibromyalgia in Taiwan Annals of the Rheumatic Diseases. 72. DOI: 10.1136/Annrheumdis-2013-Eular.1039 |
0.444 |
|
| 2012 |
Casciano R, Chulikavit M, Perrin A, Liu Z, Wang X, Babigumira J, Garrison LP. Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumor with everolimus versus sunitinib in the United States. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 226. PMID 27983058 DOI: 10.1200/Jco.2012.30.15_Suppl.E14525 |
0.644 |
|
| 2012 |
Becker R, Dembek C, White LA, Garrison LP. The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature. Expert Review of Pharmacoeconomics & Outcomes Research. 12: 775-93. PMID 23252359 DOI: 10.1586/Erp.12.65 |
0.406 |
|
| 2012 |
Wong WB, Ramsey SD, Barlow WE, Garrison LP, Veenstra DL. The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemporary Clinical Trials. 33: 1117-23. PMID 22981891 DOI: 10.1016/J.Cct.2012.08.006 |
0.36 |
|
| 2012 |
Casciano R, Chulikavit M, Perrin A, Liu Z, Wang X, Garrison LP. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. Journal of Medical Economics. 15: 55-64. PMID 22881362 DOI: 10.3111/13696998.2012.720319 |
0.377 |
|
| 2012 |
Thariani R, Veenstra DL, Carlson JJ, Garrison LP, Ramsey S. Paying for personalized care: cancer biomarkers and comparative effectiveness. Molecular Oncology. 6: 260-6. PMID 22429896 DOI: 10.1016/J.Molonc.2012.02.006 |
0.404 |
|
| 2012 |
Babigumira JB, Stergachis A, Veenstra DL, Gardner JS, Ngonzi J, Mukasa-Kivunike P, Garrison LP. Potential cost-effectiveness of universal access to modern contraceptives in Uganda. Plos One. 7: e30735. PMID 22363480 DOI: 10.1371/Journal.Pone.0030735 |
0.682 |
|
| 2012 |
Garrison L, Babigumira J, Andrade S. PCN91 The Cost-Effectiveness of Trastuzumab Over the Product Life Cycle in Portugal: A Dynamic and Societal Perspective Value in Health. 15: A425. DOI: 10.1016/J.Jval.2012.08.2131 |
0.605 |
|
| 2011 |
Garrison LP, Lalla D, Brammer MG, Wang B, Babigumira J, Perez EA. Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6133. PMID 28022481 DOI: 10.1200/jco.2011.29.15_suppl.6133 |
0.597 |
|
| 2011 |
Ramsey SD, Veenstra D, Tunis SR, Garrison L, Crowley JJ, Baker LH. How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment. Health Affairs (Project Hope). 30: 2259-68. PMID 22147853 DOI: 10.1377/Hlthaff.2010.0637 |
0.352 |
|
| 2011 |
Babigumira JB, Stergachis A, Veenstra DL, Gardner JS, Ngonzi J, Mukasa-Kivunike P, Garrison LP. Estimating the costs of induced abortion in Uganda: a model-based analysis. Bmc Public Health. 11: 904. PMID 22145859 DOI: 10.1186/1471-2458-11-904 |
0.691 |
|
| 2011 |
Flum DR, Kwon S, MacLeod K, Wang B, Alfonso-Cristancho R, Garrison LP, Sullivan SD. The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision. Annals of Surgery. 254: 860-5. PMID 21975317 DOI: 10.1097/Sla.0B013E31822F2101 |
0.343 |
|
| 2011 |
Levin A, Burgess C, Garrison LP, Bauch C, Babigumira J, Simons E, Dabbagh A. Global eradication of measles: an epidemiologic and economic evaluation. The Journal of Infectious Diseases. 204: S98-106. PMID 21666220 DOI: 10.1093/Infdis/Jir096 |
0.655 |
|
| 2011 |
Garrison LP, Bauch CT, Bresnahan BW, Hazlet TK, Kadiyala S, Veenstra DL. Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination. The Journal of Infectious Diseases. 204: S124-32. PMID 21666153 DOI: 10.1093/Infdis/Jir114 |
0.429 |
|
| 2011 |
Babigumira JB, Levin A, Burgess C, Garrison LP, Bauch CT, Braka F, Mbabazi WB, Nabyonga JO, Simons E, Dabbagh A. Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program. The Journal of Infectious Diseases. 204: S116-23. PMID 21666152 DOI: 10.1093/Infdis/Jir132 |
0.684 |
|
| 2011 |
Babigumira JB, Castelnuovo B, Stergachis A, Kiragga A, Shaefer P, Lamorde M, Kambugu A, Muwanga A, Garrison LP. Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. Plos One. 6: e18193. PMID 21464895 DOI: 10.1371/Journal.Pone.0018193 |
0.672 |
|
| 2011 |
Cross JT, Veenstra DL, Gardner JS, Garrison LP. Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007. Clinical Pharmacology and Therapeutics. 89: 429-36. PMID 21289618 DOI: 10.1038/Clpt.2010.350 |
0.335 |
|
| 2011 |
Nichols GA, Arondekar B, Garrison LP. Patient characteristics and medical care costs associated with hypertriglyceridemia. The American Journal of Cardiology. 107: 225-9. PMID 21211599 DOI: 10.1016/J.Amjcard.2010.09.010 |
0.354 |
|
| 2011 |
Roth JA, Garrison LP, Burke W, Ramsey SD, Carlson R, Veenstra DL. Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics. 14: 59-67. PMID 20407215 DOI: 10.1159/000290452 |
0.312 |
|
| 2010 |
Postma MJ, Milne G, Nelson EA, Pyenson B, Basili M, Coker R, Oxford J, Garrison LP. Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts. Expert Review of Anti-Infective Therapy. 8: 1431-9. PMID 21133667 DOI: 10.1586/Eri.10.136 |
0.314 |
|
| 2010 |
Garrison LP. Regulatory benefit-risk assessment and comparative effectiveness research: strangers, bedfellows or strange bedfellows? Pharmacoeconomics. 28: 855-65. PMID 20831293 DOI: 10.2165/11538640-000000000-00000 |
0.378 |
|
| 2010 |
Veenstra DL, Roth JA, Garrison LP, Ramsey SD, Burke W. A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 12: 686-93. PMID 20808229 DOI: 10.1097/Gim.0B013E3181Eff533 |
0.337 |
|
| 2010 |
Levy AR, Garrison LP. Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the US and Other Countries. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 13: S1-3. PMID 20618787 DOI: 10.1111/J.1524-4733.2010.00754.X |
0.332 |
|
| 2010 |
Best JH, Garrison LP. Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer. Expert Review of Pharmacoeconomics & Outcomes Research. 10: 103-14. PMID 20384557 DOI: 10.1586/Erp.10.12 |
0.367 |
|
| 2010 |
Cheng MM, Alfonso R, Best JH, Garrison LP, Bruhn D, Veenstra DL. The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment. Journal of Medical Economics. 13: 193-202. PMID 20334490 DOI: 10.3111/13696991003757500 |
0.389 |
|
| 2010 |
Towse A, Garrison LP. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics. 28: 93-102. PMID 20085386 DOI: 10.2165/11314080-000000000-00000 |
0.333 |
|
| 2010 |
Best JH, Garrison LP, Hollingworth W, Ramsey SD, Veenstra DL. Preference values associated with stage III colon cancer and adjuvant chemotherapy. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 19: 391-400. PMID 20084462 DOI: 10.1007/S11136-010-9589-5 |
0.344 |
|
| 2010 |
Garrison LP, Mansley EC, Abbott TA, Bresnahan BW, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 13: 8-13. PMID 19883405 DOI: 10.1111/J.1524-4733.2009.00660.X |
0.407 |
|
| 2010 |
Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, Mullins CD, Mycka JM, Seal B, Shi L. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 13: 3-7. PMID 19874571 DOI: 10.1111/J.1524-4733.2009.00663.X |
0.437 |
|
| 2010 |
Wang S, Huang H, Shi H, Dun M, Chen K, Chang E, Korves C, Dhawan R, Cakana A, van de Velde H, Esseltine D, Garrison L. PSY29 MODELING THE COST-EFFECTIVENESS OF BORTEZOMIB FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES Value in Health. 13: A210. DOI: 10.1016/S1098-3015(10)73031-X |
0.373 |
|
| 2010 |
Flum DR, Kwon S, MacLeod K, Wang B, Alfonso R, Garrison LP, Sullivan SD. The impact of accreditation-based coverage decisions on the safety and cost of bariatric surgery Journal of the American College of Surgeons. 211: S96-S97. DOI: 10.1016/J.Jamcollsurg.2010.06.254 |
0.343 |
|
| 2009 |
Babigumira JB, Castelnuovo B, Lamorde M, Kambugu A, Stergachis A, Easterbrook P, Garrison LP. Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. Bmc Health Services Research. 9: 192. PMID 19845963 DOI: 10.1186/1472-6963-9-192 |
0.666 |
|
| 2009 |
Carlson JJ, Garrison LP, Sullivan SD. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. Journal of Managed Care Pharmacy : Jmcp. 15: 683-7. PMID 19803557 DOI: 10.18553/Jmcp.2009.15.8.683 |
0.412 |
|
| 2009 |
Garrison LP, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 1118-23. PMID 19624617 DOI: 10.1111/J.1524-4733.2009.00572.X |
0.407 |
|
| 2009 |
Garrison LP. Editorial: On the benefits of modeling using QALYs for societal resource allocation: the model is the message. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: S36-7. PMID 19250130 DOI: 10.1111/J.1524-4733.2009.00520.X |
0.391 |
|
| 2009 |
Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 20-7. PMID 18647257 DOI: 10.1111/J.1524-4733.2008.00415.X |
0.41 |
|
| 2009 |
Wang S, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, van de Velde H, Esseltine D, Garrison L. The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States. Blood. 114: 1379-1379. DOI: 10.1182/Blood.V114.22.1379.1379 |
0.481 |
|
| 2009 |
Garrison L, Bauch C, Babigumira J. VA3 GLOBAL MEASLES ERADICATION: COST-EFFECTIVENESS AND IMPLICATIONS FOR GHANA, 2020–2049 Value in Health. 12: A228. DOI: 10.1016/S1098-3015(10)74114-0 |
0.641 |
|
| 2009 |
Bresnahan B, Babigumira J, Veenstra D, Bauch C, Garrison L. PIN39 ASSESSING DISEASE BURDEN FOR MEASLES USING A CLINICAL AND HEALTH OUTCOMES APPROACH: A FOCUS ON LOWER-INCOME COUNTRIES Value in Health. 12: A117. DOI: 10.1016/S1098-3015(10)73647-0 |
0.576 |
|
| 2008 |
Babigumira J, Castelnuovo B, Lamorde M, Muwanga A, Kambugu A, Easterbrook P, Garrison L. PIN9 THE WORKFORCE AND COST IMPLICATIONS OF SUBSTITUTING NURSES AND PHARMACISTS FOR DOCTORS IN THE FOLLOW-UP OF PATIENTS WITH AIDS ON ANTIRETROVIRALTHERAPY IN UGANDA Value in Health. 11: A94-A95. DOI: 10.1016/S1098-3015(10)70307-7 |
0.621 |
|
| 2008 |
Sullivan S, Garrison L, Rinde H, Kolberg J, Moler E, Urdea M. OM4 LONG-TERM COST-EFFECTIVENESS OF A DIABETES RISK SCORE IN CLINICAL PRACTICE Value in Health. 11: A21. DOI: 10.1016/S1098-3015(10)70079-6 |
0.327 |
|
| 2007 |
Garrison LP, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 110: 489-98. PMID 17592827 DOI: 10.1002/Cncr.22806 |
0.365 |
|
| 2007 |
Garrison LP, Towse A, Bresnahan BW. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Affairs (Project Hope). 26: 684-95. PMID 17485745 DOI: 10.1377/Hlthaff.26.3.684 |
0.326 |
|
| 2007 |
Garrison LP, Austin MJF. The economics of personalized medicine: A model of incentives for value creation and capture Drug Information Journal. 41: 501-509. DOI: 10.1177/009286150704100408 |
0.36 |
|
| 2007 |
Meckley L, Austin M, Garrison L, Veenstra D. PCV56 THE COST-EFFECTIVENESS LANDSCAPE OF GENETIC TESTING WITH WARFARIN THERAPY Value in Health. 10: A53. DOI: 10.1016/S1098-3015(10)68698-6 |
0.353 |
|
| 2007 |
Sander B, Nizam A, Garrison L, Postma M, Halloran M, Longini Jr I. IN4 ECONOMIC EVALUATION OF INFLUENZA PANDEMIC MITIGATION STRATEGIES IN THE US USING A STOCHASTIC MICROSIMULATION INFLUENZA MODEL Value in Health. 10: A19. DOI: 10.1016/S1098-3015(10)68589-0 |
0.37 |
|
| 2006 |
Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, ... ... Garrison LP, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. British Journal of Cancer. 94: 1122-9. PMID 16622438 DOI: 10.1038/sj.bjc.6603059 |
0.368 |
|
| 2006 |
Morden NE, Garrison LP. Implications of Part D for mentally ill dual eligibles: a challenge for Medicare. Health Affairs (Project Hope). 25: 491-500. PMID 16522603 DOI: 10.1377/Hlthaff.25.2.491 |
0.316 |
|
| 1997 |
Hornberger JC, Best JH, Garrison LP. Cost-effectiveness of repeat medical procedures: Kidney transplantation as an example Medical Decision Making. 17: 363-372. PMID 9343794 DOI: 10.1177/0272989X9701700401 |
0.385 |
|
| 1992 |
Garrison LP. Assessment of the effectiveness of supply-side cost-containment measures. Health Care Financing Review. 1991: 13-20. PMID 25372721 |
0.352 |
|
| 1986 |
Garrison LP, Wilensky GR. Cost containment and incentives for technology Health Affairs (Project Hope). 5: 46-58. PMID 3527916 DOI: 10.1377/Hlthaff.5.2.46 |
0.368 |
|
| 1984 |
Garrison LP, Bowman MA, Perrin EB. Estimating physician requirements for neurology: A needs-based approach Neurology. 34: 1218-1227. PMID 6540408 DOI: 10.1212/Wnl.34.9.1218 |
0.304 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2018 |
Csanádi M, Kaló Z, Prins CP, Grélinger E, Menczelné Kiss A, Fricke F, Fuksa L, Tesar T, Manova M, Lorenzovici L, Vokó Z, Garrison LP. The implications of external price referencing on pharmaceutical list prices in Europe Health Policy and Technology. 7: 243-250. DOI: 10.1016/J.Hlpt.2018.07.005 |
0.299 |
|
| 2019 |
Hart MR, Garrison LP, Doyle DL, Jarvik GP, Watkins J, Devine B. Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 1231-1239. PMID 31708059 DOI: 10.1016/J.Jval.2019.05.015 |
0.298 |
|
| 2016 |
Agapova M, Bresnahan BB, Higashi M, Kessler L, Garrison LP, Devine B. A proposed approach for quantitative benefit-risk assessment in diagnostic radiology guideline development: the American College of Radiology Appropriateness Criteria Example. Journal of Evaluation in Clinical Practice. PMID 27762080 DOI: 10.1111/Jep.12635 |
0.297 |
|
| 2019 |
Li M, Basu A, Bennette CS, Veenstra DL, Garrison LP. Do cancer treatments have option value? Real-world evidence from metastatic melanoma. Health Economics. 28: 855-867. PMID 31237095 DOI: 10.1002/Hec.3899 |
0.297 |
|
| 2014 |
Carlson JJ, Gries KS, Yeung K, Sullivan SD, Garrison LP. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Applied Health Economics and Health Policy. 12: 231-8. PMID 24664994 DOI: 10.1007/S40258-014-0093-X |
0.296 |
|
| 2006 |
Di Costanzo F, Sobrero A, Twelves C, Douillard J, Giuliani G, Patel K, Garrison LP, Cassidy J. Capecitabine (X) vs. bolus 5-FU/LV as adjuvant chemotherapy for patients (pts) with Dukes’ C colon cancer: economic evaluation in an Italian hospital setting Journal of Clinical Oncology. 24: 13518-13518. DOI: 10.1200/jco.2006.24.18_suppl.13518 |
0.296 |
|
| 2021 |
Garrison LP, Pezalla E, Towse A, Yang H, Faust E, Wu EQ, Li N, Sawyer EK, Recht M. Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 24: 1628-1633. PMID 34711363 DOI: 10.1016/j.jval.2021.05.008 |
0.296 |
|
| 2007 |
Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 10: 326-35. PMID 17888097 DOI: 10.1111/J.1524-4733.2007.00186.X |
0.293 |
|
| 2006 |
Garrison LP, Austin MJ. Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. Health Affairs (Project Hope). 25: 1281-90. PMID 16966724 DOI: 10.1377/Hlthaff.25.5.1281 |
0.291 |
|
| 1981 |
Wills J, Garrison LP, Peterson ML. Manpower requirements in ophthalmology Ophthalmology. 88. PMID 7335326 DOI: 10.1016/S0161-6420(81)34888-X |
0.29 |
|
| 2011 |
Garrison LP, Bresnahan BW, Higashi MK, Hollingworth W, Jarvik JG. Innovation in diagnostic imaging services: assessing the potential for value-based reimbursement. Academic Radiology. 18: 1109-14. PMID 21703880 DOI: 10.1016/J.Acra.2011.04.007 |
0.29 |
|
| 2012 |
Casciano R, Chulikavit M, Sriprasert M, Liu Z, Wang X, Garrison LP. Health plan budget impact of introducing everolimus for treatment of advanced progressive pancreatic neuroendocrine tumors in the United States. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 229. PMID 27983024 DOI: 10.1200/Jco.2012.30.4_Suppl.229 |
0.29 |
|
| 2010 |
Garrison LP, Neumann PJ, Radensky P, Walcoff SD. A flexible approach to evidentiary standards for comparative effectiveness research. Health Affairs (Project Hope). 29: 1812-7. PMID 20921480 DOI: 10.1377/Hlthaff.2010.0692 |
0.29 |
|
| 2011 |
Ramsey SD, Barlow WE, Moinpour C, Gonzalez-Angulo AM, Hortobagyi GN, Veenstra DL, Garrison LP, Tunis SR, Baker LH. Incorporating comparative effectiveness research study endpoints into the treatment for positive-node, endocrine-responsive breast cancer (RxPONDER) study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS101. PMID 28022861 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps101 |
0.29 |
|
| 2015 |
Towse A, Pistollato M, Mestre-Ferrandiz J, Khan Z, Kaura S, Garrison L. European Union Pharmaceutical Markets: A Case for Differential Pricing? International Journal of the Economics of Business. 22: 263-275. DOI: 10.1080/13571516.2015.1045747 |
0.289 |
|
| 2018 |
de Montigny S, Adamson BJS, Mâsse BR, Garrison LP, Kublin JG, Gilbert PB, Dimitrov DT. Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study. Scientific Reports. 8: 6066. PMID 29666455 DOI: 10.1038/S41598-018-24268-4 |
0.288 |
|
| 2013 |
Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Review of Pharmacoeconomics & Outcomes Research. 13: 735-41. PMID 24219049 DOI: 10.1586/14737167.2013.847367 |
0.287 |
|
| 2012 |
Thariani R, Wong W, Carlson JJ, Garrison L, Ramsey S, Deverka PA, Esmail L, Rangarao S, Hoban CJ, Baker LH, Veenstra DL. Prioritization in comparative effectiveness research: the CANCERGEN Experience. Medical Care. 50: 388-93. PMID 22274803 DOI: 10.1097/Mlr.0B013E3182422A3B |
0.285 |
|
| 2016 |
Segal JB, Kallich JD, Oppenheim ER, Garrison LP, Iqbal SU, Kessler M, Caleb Alexander G. Using Certification to Promote Uptake of Real-World Evidence by Payers. Journal of Managed Care & Specialty Pharmacy. 22: 191-6. PMID 27003547 DOI: 10.18553/Jmcp.2016.22.3.191 |
0.285 |
|
| 2011 |
Sullivan SD, Garrison LP, Rinde H, Kolberg J, Moler EJ. Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score. Journal of Medical Economics. 14: 609-16. PMID 21740291 DOI: 10.3111/13696998.2011.602160 |
0.284 |
|
| 2009 |
Garrison LP. Will pharmacogenomics disrupt the U.S. health care system? No. Public Health Genomics. 12: 185-90. PMID 19204422 DOI: 10.1159/000189632 |
0.284 |
|
| 2006 |
Sander B, Hayden FG, Gyldmark M, Garrison LP. Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. Pharmacoeconomics. 24: 373-86. PMID 16605283 DOI: 10.2165/00019053-200624040-00007 |
0.283 |
|
| 2010 |
Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy (Amsterdam, Netherlands). 96: 179-90. PMID 20226559 DOI: 10.1016/J.Healthpol.2010.02.005 |
0.281 |
|
| 2019 |
van der Goes DN, Ney JP, Garrison LP. Determinants of specialist physician ambulatory visits: a neurology example. Journal of Medical Economics. 1. PMID 31081729 DOI: 10.1080/13696998.2019.1618861 |
0.281 |
|
| 2013 |
Wang B, Fang C, Furnback W, Ney J, Garrison L. Estimating the cost-effectiveness of pregabalin for the treatment of severe Fibromyalgia in Taiwan Value in Health. 16: A105. DOI: 10.1016/j.jval.2013.03.496 |
0.281 |
|
| 2011 |
Best JH, Rubin RR, Peyrot M, Li Y, Yan P, Malloy J, Garrison LP. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care. 34: 314-9. PMID 21270189 DOI: 10.2337/Dc10-1119 |
0.28 |
|
| 2016 |
Thompson M, Henshall C, Garrison LP, Griffin AD, Coyle D, Long S, Khayat ZA, Anger DL, Yu R. Targeting improved patient outcomes using innovative product listing agreements: a survey of Canadian and international key opinion leaders. Clinicoeconomics and Outcomes Research : Ceor. 8: 427-33. PMID 27616892 DOI: 10.2147/Ceor.S96616 |
0.279 |
|
| 2020 |
Smith SM, Dworkin RH, Turk DC, McDermott M, Eccleston C, Farrar JT, Rowbotham MC, Bhangwagar Z, Burke LB, Cowan P, Ellenberg SS, Evans SR, Freeman RL, Garrison LP, Iyengar S, et al. Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. Pain. PMID 32520773 DOI: 10.1097/J.Pain.0000000000001952 |
0.278 |
|
| 2018 |
Zimmermann M, Vodicka E, Holman A, Garrison LP. Heart rate variability testing: could it change spending for rheumatoid arthritis patients in the United States? An exploratory economic analysis. Journal of Medical Economics. 1-21. PMID 29701508 DOI: 10.1080/13696998.2018.1470519 |
0.278 |
|
| 2011 |
Bergenstal RM, Garrison LP, Wintle M, Blickensderfer A, Wade R, Hou L, Miller LA, Scism-Bacon J, Zagar A, Misurski D, Herman WH. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. Current Medical Research and Opinion. 27: 531-40. PMID 21219119 DOI: 10.1185/03007995.2010.545814 |
0.277 |
|
| 2017 |
Carlson JJ, Chen S, Garrison LP. Performance-Based Risk-Sharing Arrangements: An Updated International Review. Pharmacoeconomics. PMID 28695544 DOI: 10.1007/S40273-017-0535-Z |
0.274 |
|
| 2019 |
Garrison LP, Towse A. A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision Medicine. Journal of Managed Care & Specialty Pharmacy. 25: 1082-1087. PMID 31556828 DOI: 10.18553/Jmcp.2019.25.10.1082 |
0.274 |
|
| 2019 |
Rochau U, Vukićević D, Angerer S, Schaffner M, Qerimi Rushaj V, Conrads-Frank A, Jahn B, Hackl W, Ammenwerth E, Stummer H, Garrison L, Weger R, Willenbacher E, Willenbacher W, Siebert U. PCN163 SEQUENTIAL TREATMENT REGIMENS FOR ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A COST-EFFECTIVENESS ANALYSIS INCLUDING EXPERIENCE FROM REAL-WORLD DATA Value in Health. 22: S467. DOI: 10.1016/j.jval.2019.09.359 |
0.274 |
|
| 2017 |
Agapova M, Bresnahan BW, Linnau KF, Garrison LP, Higashi M, Kessler L, Devine B. Toward a Framework for Benefit-Risk Assessment in Diagnostic Imaging: Identifying Scenario-specific Criteria. Academic Radiology. PMID 28372958 DOI: 10.1016/J.Acra.2017.02.002 |
0.271 |
|
| 1990 |
Garrison LP. Medicaid, the uninsured, and national health spending: Federal policy implications Health Care Financing Review. 12: 167-170. PMID 10113492 |
0.271 |
|
| 2016 |
Suh K, Carlson J, Garrison L. Projecting the Potential Cost Effectiveness of Ocrelizumab Versus Standard Care in Primary Progressive Multiple Sclerosis Patients Under Alternative Pricing Scenarios Value in Health. 19: A62-A63. DOI: 10.1016/J.JVAL.2016.03.200 |
0.269 |
|
| 2011 |
Bergenstal RM, Garrison LP, Miller LA, Hou L, Blickensderfer A, Zagar A, Stanley S, Bhargava A, Wade R, Herman WH. Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. Current Medical Research and Opinion. 27: 2335-42. PMID 22085180 DOI: 10.1185/03007995.2011.628305 |
0.268 |
|
| 1983 |
Bowman MA, Katzoff JM, Garrison LP, Wills J. Estimates of Physician Requirements for 1990 for the Specialties of Neurology, Anesthesiology, Nuclear Medicine, Pathology, Physical Medicine and Rehabilitation, and Radiology: A Further Application of the GMENAC Methodology Jama: the Journal of the American Medical Association. 250: 2623-2627. PMID 6355541 DOI: 10.1001/Jama.1983.03340190025025 |
0.268 |
|
| 2008 |
Garrison LP, Carlson RJ, Carlson JJ, Kuszler PC, Meckley LM, Veenstra DL. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metabolism Reviews. 40: 377-401. PMID 18464050 DOI: 10.1080/03602530801952500 |
0.267 |
|
| 2009 |
Sander B, Nizam A, Garrison LP, Postma MJ, Halloran ME, Longini IM. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 226-33. PMID 18671770 DOI: 10.1111/J.1524-4733.2008.00437.X |
0.267 |
|
| 2014 |
Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP. Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies. Pharmacoepidemiology and Drug Safety. 23: 268-77. PMID 24892175 DOI: 10.1002/Pds.3559 |
0.266 |
|
| 2018 |
Devine EB, Perfetto E, Pickard AS, Schumock GT, Segal JB, Cannon E, Gagnon JP, Brixner DI, Garrison LP, Murray MD. Nine years of comparative effectiveness research education and training: initiative supported by the PhRMA Foundation. Journal of Comparative Effectiveness Research. PMID 29464964 DOI: 10.2217/Cer-2017-0059 |
0.265 |
|
| 2008 |
Cross J, Garrison L, Sullivan S. PHP16 IMPROVING HEALTH TECHNOLOGY APPRAISAL AND DECISION-MAKING: WHAT HAS THE BRITISH PARLIAMENT'S INQUIRY OF NICE TAUGHT US? Value in Health. 11: A33-A34. DOI: 10.1016/S1098-3015(10)70115-7 |
0.265 |
|
| 1997 |
Sullivan SD, Garrison LP, Best JH. The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant Journal of the American Society of Nephrology. 8: 1592-1598. PMID 9335389 |
0.264 |
|
| 2009 |
Bauch CT, Szusz E, Garrison LP. Scheduling of measles vaccination in low-income countries: projections of a dynamic model. Vaccine. 27: 4090-8. PMID 19410622 DOI: 10.1016/J.Vaccine.2009.04.079 |
0.264 |
|
| 2010 |
Szusz EK, Garrison LP, Bauch CT. A review of data needed to parameterize a dynamic model of measles in developing countries. Bmc Research Notes. 3: 75. PMID 20233414 DOI: 10.1186/1756-0500-3-75 |
0.264 |
|
| 2019 |
Quinn C, Garrison L, Briggs A, Pownell A, Atkins M, de Pouvourville G, Harrington K, Ascierto P, McEwan P, Doan J, Wagner S, Borrill J, Wu E. PCN57 A MULTI-STAKEHOLDER PERSPECTIVE ON THE CHALLENGES IN DEMONSTRATING THE LONG-TERM BENEFIT OF CANCER IMMUNOTHERAPY Value in Health. 22: S446. DOI: 10.1016/J.Jval.2019.09.254 |
0.264 |
|
| 2012 |
Wang B, Garrison L. PMS35 The Cost-Effectiveness of Pegloticase in the Treatment of Refractory Chronic Gout Value in Health. 15: A39-A40. DOI: 10.1016/j.jval.2012.03.224 |
0.262 |
|
| 2023 |
Meunier A, Longworth L, Gomes M, Ramagopalan S, Garrison LP, Popat S. Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers. Pharmacoeconomics. 1-15. PMID 37296369 DOI: 10.1007/s40273-023-01281-8 |
0.261 |
|
| 2018 |
Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP, Douglas MP, Weldon CB. Insurance coverage for genomic tests. Science (New York, N.Y.). 360: 278-279. PMID 29674586 DOI: 10.1126/Science.Aas9268 |
0.26 |
|
| 2006 |
Garrison LP, Perez EA, Dueck A, Lalla D, Paton V, Lubeck D. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 6023. PMID 27954582 DOI: 10.1200/Jco.2006.24.18_Suppl.6023 |
0.258 |
|
| 2010 |
Garrison LP. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle. The Oncologist. 15: 49-57. PMID 20237218 DOI: 10.1634/Theoncologist.2010-S1-49 |
0.257 |
|
| 2013 |
Garrison LP. Universal health coverage--big thinking versus big data. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 16: S1-3. PMID 23317638 DOI: 10.1016/J.Jval.2012.10.016 |
0.257 |
|
| 2022 |
Incze A, Kaló Z, Espín J, Kiss É, Kessabi S, Garrison LP. Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications. Frontiers in Pharmacology. 13: 815029. PMID 35462921 DOI: 10.3389/fphar.2022.815029 |
0.257 |
|
| 2012 |
Sun P, Garrison LP. Retrospective outcomes studies for orphan diseases: challenges and opportunities. Current Medical Research and Opinion. 28: 665-7. PMID 22432785 DOI: 10.1185/03007995.2012.673480 |
0.256 |
|
| 2017 |
Agapova M, Bresnahan BW, Linnau KF, Garrison LP, Higashi M, Kessler L, Devine B. Using the Analytic Hierarchy Process for Prioritizing Imaging Tests in Diagnosis of Suspected Appendicitis. Academic Radiology. PMID 28363670 DOI: 10.1016/J.Acra.2017.01.001 |
0.256 |
|
| 2014 |
Carlson JJ, Gries K, Yeung K, Sullivan SD, Garrison LP. Authors' reply to Curto and Garattini: "Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers". Applied Health Economics and Health Policy. 12: 567-8. PMID 25124263 DOI: 10.1007/S40258-014-0119-4 |
0.255 |
|
| 2008 |
Takemoto SK, Arns W, Bunnapradist S, Garrison LP, Guirado L, Kalo Z, Oniscu G, Opelz G, Scolari MP, Stefoni S, Yaqoob M, Brennan DC. Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research. Transplantation. 86: 18-25. PMID 18622271 DOI: 10.1097/Tp.0B013E31817D4Df5 |
0.254 |
|
| 1993 |
Clemens K, Garrison LP, Jones A, Macdonald F. Strategic Use of Pharmacoeconomic Research in Early Drug Development and Global Pricing Pharmacoeconomics. 4: 315-322. PMID 10146870 DOI: 10.2165/00019053-199304050-00002 |
0.252 |
|
| 2024 |
Jiao B, Carlson JJ, Garrison LP, Basu A. Evaluating Policies of Expanding vs. Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. PMID 38191022 DOI: 10.1016/j.jval.2023.12.013 |
0.252 |
|
| 2008 |
Bresnahan B, Koprowicz K, Choudhury S, Garrison L, Wong E. PHP35 CHARACTERIZING PHARMACY AND MEDICAL CLAIMS FOR A PRIVATE INSURANCE POLYPHARMACY POPULATION Value in Health. 11: A39. DOI: 10.1016/S1098-3015(10)70133-9 |
0.25 |
|
| 2019 |
Zamora Talaya M, Garrison L, Unuigbe A, Towse A. PNS78 RECONCILING ACEA AND MCDA: IS THERE A WAY FORWARD FOR MEASURING COST-EFFECTIVENESS IN THE U.S. HEALTHCARE SETTING? Value in Health. 22: S775. DOI: 10.1016/j.jval.2019.09.1980 |
0.248 |
|
| 2016 |
Adamson B, Jain R, Garrison L, Lutz B. SMARTPHONE-ENHANCED RAPID INFLUENZA TESTS: A COST-EFFECTIVENESS ANALYSIS Value in Health. 19: A302. DOI: 10.1016/j.jval.2016.03.708 |
0.248 |
|
| 2009 |
Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology. 135: 1483-93. PMID 19430813 DOI: 10.1007/S00432-009-0595-3 |
0.248 |
|
| 2013 |
Guzauskas GF, Garrison LP, Stock J, Au S, Doyle DL, Veenstra DL. Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 84-7. PMID 22836698 DOI: 10.1038/Gim.2012.92 |
0.247 |
|
| 2021 |
Park JY, Marcum ZA, Garrison LP. Toward a broader concept of societal value: family spillovers in Alzheimer's disease. International Journal of Technology Assessment in Health Care. 38: e7. PMID 36317687 DOI: 10.1017/S0266462321000593 |
0.245 |
|
| 2013 |
Lin VW, Wong ES, Wright A, Flum DR, Garrison LP, Alfonso-Cristancho R, Sullivan SD. Association between health-related quality of life and body mass after adjustable gastric banding: a nonlinear approach. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 16: 823-9. PMID 23947976 DOI: 10.1016/J.Jval.2013.05.001 |
0.244 |
|
| 2022 |
Boustani M, Doty EG, Garrison LP, Smolen LJ, Belger M, Klein TM, Murphy DR, Burge R, Wall JK, Johnston JA. Assessing the Cost-effectiveness of a Hypothetical Disease-Modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease. Clinical Therapeutics. PMID 36210219 DOI: 10.1016/j.clinthera.2022.09.008 |
0.243 |
|
| 1985 |
Garrison LP, Bowman MA, Perrin EB. Estimating physician requirements for neurology Neurology. 35: 1530-1530. DOI: 10.1212/Wnl.35.10.1530 |
0.241 |
|
| 2019 |
Garau M, Towse A, Garrison L, Housman L, Ossa D. Can and should value-based pricing be applied to molecular diagnostics? Personalized Medicine. 10: 61-72. PMID 29783475 DOI: 10.2217/pme.12.99 |
0.24 |
|
| 2011 |
van der Goes D, Willke R, Garrison L. PCV44 CHANGING COST-EFFECTIVENESS EARLY IN THE PRODUCT LIFE CYCLE: THE EXAMPLE OF CLOPIDOGREL BISULFATE Value in Health. 14: A40. DOI: 10.1016/j.jval.2011.02.231 |
0.238 |
|
| 2012 |
Cheng MM, Ramsey SD, Devine EB, Garrison LP, Bresnahan BW, Veenstra DL. Systematic review of comparative effectiveness data for oncology orphan drugs. The American Journal of Managed Care. 18: 47-62. PMID 22435748 |
0.238 |
|
| 2020 |
Skirko JR, James KT, Garrison LP, Weaver EM. Development of a Sleep Apnea-Specific Health State Utility Algorithm. Jama Otolaryngology-- Head & Neck Surgery. PMID 31999308 DOI: 10.1001/Jamaoto.2019.4469 |
0.236 |
|
| 2009 |
Garrison L, Bauch C, Bresnahan B, Hazlet T, Kadiyala S, Veenstra D. VA3 A GLOBAL COST-EFFECTIVENESS EVALUATION OF THE IMPACT OF POTENTIAL INNOVATIONS IN MEASLES VACCINATION Value in Health. 12: A9. DOI: 10.1016/S1098-3015(10)73105-3 |
0.234 |
|
| 2013 |
Lin VW, Wright A, Flum DR, Garrison LP, Alfonso-Cristancho R, Sullivan SD. Patients' experience and outcomes after laparoscopic adjustable gastric banding in Washington state. Surgery For Obesity and Related Diseases : Official Journal of the American Society For Bariatric Surgery. 9: 701-5. PMID 22578289 DOI: 10.1016/J.Soard.2012.03.011 |
0.233 |
|
| 2009 |
Veenstra DL, Garrison LP, Ramsey SD. CHAPTER 36 – Economic Issues and Genomic Medicine Genomic and Personalized Medicinevolumes I & Ii. 424-433. DOI: 10.1016/B978-0-12-369420-1.00036-6 |
0.232 |
|
| 2012 |
Wong ES, Wang BC, Alfonso-Cristancho R, Flum DR, Sullivan SD, Garrison LP, Arterburn DE. BMI trajectories among the severely obese: results from an electronic medical record population. Obesity (Silver Spring, Md.). 20: 2107-12. PMID 22314622 DOI: 10.1038/Oby.2012.29 |
0.231 |
|
| 2005 |
Garrison L, Patel K, Sengupta N, Green J, Best J, Ramsey S. PCN7 THE COST-EFFECTIVENESS OF CAPECITABINE AS ADJUVANT ORAL CHEMOTHERAPY FOR DUKE'S C COLON CANCER Value in Health. 8: 345. DOI: 10.1016/S1098-3015(10)62913-0 |
0.229 |
|
| 2022 |
Sullivan SD, Sullivan KD, Dabbous O, Garrison LP. International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments. Journal of Managed Care & Specialty Pharmacy. 28: 566-572. PMID 35471069 DOI: 10.18553/jmcp.2022.28.5.566 |
0.227 |
|
| 2017 |
Banerjee S, Roland CL, Willke R, Mardekian J, Garrison LP. Prevalence of and Comorbid Health Conditions Associated With Pediatric Prescription Opioid Use in the US. Journal of Pain & Palliative Care Pharmacotherapy. 1-10. PMID 29261401 DOI: 10.1080/15360288.2017.1407860 |
0.219 |
|
| 2022 |
Garrison LP, Kleinermans D. Is the world ready for gene therapy? Haemophilia : the Official Journal of the World Federation of Hemophilia. 5-8. PMID 35318781 DOI: 10.1111/hae.14439 |
0.215 |
|
| 2015 |
Adamson B, Bounthavong M, Kublin J, Garrison L. Cost-Effectiveness Analysis of a Partially Effective Hiv Vaccine In San Francisco Value in Health. 18: A237. DOI: 10.1016/J.JVAL.2015.03.1377 |
0.213 |
|
| 2011 |
Wong ES, Wang BC, Garrison LP, Alfonso-Cristancho R, Flum DR, Arterburn DE, Sullivan SD. Examining the BMI-mortality relationship using fractional polynomials. Bmc Medical Research Methodology. 11: 175. PMID 22204699 DOI: 10.1186/1471-2288-11-175 |
0.211 |
|
| 1986 |
Evans RW, Manninen DL, Garrison LP, Maier AM. Donor Availability as the Primary Determinant of the Future of Heart Transplantation Jama: the Journal of the American Medical Association. 255: 1892-1898. PMID 3512878 DOI: 10.1001/Jama.1986.03370140090030 |
0.211 |
|
| 2022 |
Garrison LP, Jiao B, Dabbous O. Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the "Age of Cures" and Their Implications for Dynamic Efficiency. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. PMID 36336584 DOI: 10.1016/j.jval.2022.09.010 |
0.207 |
|
| 2021 |
Asukai Y, Briggs A, Garrison LP, Geisler BP, Neumann PJ, Ollendorf DA. Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. Pharmacoeconomics. PMID 34557996 DOI: 10.1007/s40273-021-01088-5 |
0.207 |
|
| 2023 |
Garrison LP, Lo AW, Finkel RS, Deverka PA. A review of economic issues for gene-targeted therapies: Value, affordability, and access. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics. PMID 36854952 DOI: 10.1002/ajmg.c.32037 |
0.207 |
|
| 2012 |
Sullivan S, Moler E, Garrison L. PDB31 Targeted Cost Saving Strategies in Diabetes Prevention Using Risk Stratification Value in Health. 15: A176. DOI: 10.1016/j.jval.2012.03.952 |
0.198 |
|
| 2011 |
Wang B, Garrison L, Alfonso-Cristancho R, Wong E, Flum D, Arterburn D, Sullivan S. PSY16 PROJECTING THE LIFETIME ECONOMIC COSTS OF OBESITY: A BMI TRAJECTORY-BASED MODEL Value in Health. 14: A61-A62. DOI: 10.1016/j.jval.2011.02.349 |
0.194 |
|
| 2024 |
Ramagopalan SV, Diaz J, Mitchell G, Garrison LP, Kolchinsky P. Is the price right? Paying for value today to get more value tomorrow. Bmc Medicine. 22: 45. PMID 38287326 DOI: 10.1186/s12916-024-03262-w |
0.182 |
|
| 2016 |
Wang B, Nguyen H, Furnback W, Guzauskas G, Hurd J, Garrison L. Estimating The Societal Costs Associated With Glp-1ras In The United States For The Treatment of Type 2 Diabetes Value in Health. 19: A7. DOI: 10.1016/j.jval.2016.03.053 |
0.182 |
|
| 2016 |
Wang B, Nguyen H, Furnback W, Guzauskas G, Hurd J, Garrison L. ESTIMATING THE COST TO SOCIETY FOR EXENATIDE QW AND INSULIN GLARGINE IN THE UNITED STATES FOR THE TREATMENT OF TYPE 2 DIABETES Value in Health. 19: A201. DOI: 10.1016/j.jval.2016.03.1288 |
0.181 |
|
| 2006 |
Ramsey SD, Veenstra DL, Garrison LP, Carlson R, Billings P, Carlson J, Sullivan SD. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. The American Journal of Managed Care. 12: 197-202. PMID 16610921 |
0.181 |
|
| 2011 |
Vecino-Ortiz A, Garrison L, Alfonso-Cristancho R. PMD24 GLYCOSYLATED HEMOGLOBIN OR FASTING GLUCOSE TESTING FOR SCREENING DIABETES IN COLOMBIA: A COST-EFFECTIVENESS ANALYSIS Value in Health. 14: A83. DOI: 10.1016/j.jval.2011.02.464 |
0.181 |
|
| 2014 |
Tung A, Devine E, Garrison L. Assessing The Likely Cost-Utility Of Alemtuzumab Versus Rabbit Anti-Thymocte Globulin As Induction Therapy For High-Risk Kidney Transplant Recipients Value in Health. 17: A294. DOI: 10.1016/j.jval.2014.03.1709 |
0.18 |
|
| 2014 |
Wang B, Nguyen H, Felber E, Furnback W, Roth J, Garrison L. Comparing the projected cost per HbA1c reduction of exenatide QW versus liraglutide 1.8 mg for the treatment of type 2 diabetes mellitus using alternate data sources Value in Health. 17: A250. DOI: 10.1016/j.jval.2014.03.1456 |
0.177 |
|
| 2022 |
Neumann PJ, Garrison LP, Willke RJ. The History and Future of the "ISPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness Analysis. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. PMID 35279370 DOI: 10.1016/j.jval.2022.01.010 |
0.174 |
|
| 2014 |
Bajaj P, Willke R, Sullivan S, Garrison L. What Drives Private Investment In Health Economics And Outcomes Research? Value in Health. 17: A22. DOI: 10.1016/j.jval.2014.03.138 |
0.172 |
|
| 2014 |
Kling C, Varghese T, Garrison L, Veenstra D, Flum D, Alfonso-Cristancho R. Assessing the potential cost-effectiveness of a smoking cessation program prior to elective surgery Value in Health. 17: A38. DOI: 10.1016/j.jval.2014.03.230 |
0.171 |
|
| 2007 |
Scheithauer W, Cassidy J, Figer A, Wong R, Koski S, Lichinitser M, Yang T, Clarke S, Diaz-Rubio E, Garrison L. A comparison of medical resource use for 4 chemotherapy regimens as first-line treatment for metastatic colorectal cancer (MCRC): XELOX vs. FOLFOX4 ± bevacizumab (A) Journal of Clinical Oncology. 25: 4098-4098. DOI: 10.1200/jco.2007.25.18_suppl.4098 |
0.171 |
|
| 2023 |
Wang B, Wu E, Rassloff D, Moore M, Bridger P, Garrison LP. Estimating the Potential Economic Impact of Tissue Valve Replacement for Heart Valve Disease in China: Patient-Level and Population-Level Cost-Benefit Simulation Analyses. Value in Health Regional Issues. 35: 19-26. PMID 36805389 DOI: 10.1016/j.vhri.2023.01.002 |
0.165 |
|
| 2012 |
Best JH, Lavillotti K, DeYoung MB, Garrison LP. The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review. Diabetes, Obesity & Metabolism. 14: 387-98. PMID 22074017 DOI: 10.1111/j.1463-1326.2011.01533.x |
0.161 |
|
| 2024 |
Wong W, Kowal S, To TM, Patel A, Veenstra D, Garrison L, Li M. The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations. Future Oncology (London, England). PMID 38258557 DOI: 10.2217/fon-2023-0514 |
0.16 |
|
| 1984 |
Greenwald HP, Peterson ML, Garrison LP, Hart LG, Moscovice IS, Hall TL, Perrin EB. Interspecialty variation in office-based care Medical Care. 22: 14-29. PMID 6694458 DOI: 10.1097/00005650-198401000-00002 |
0.16 |
|
| 2021 |
Desai N, Xie J, Wang Y, Sutton MB, Whang J, Fine JT, Garrison LP. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit. Clinical Therapeutics. PMID 34911641 DOI: 10.1016/j.clinthera.2021.11.006 |
0.16 |
|
| 2014 |
Gallego C, Shirts B, Garrison L, Jarvik G, Veenstra D. Can Next Generation Sequencing Save Lives and Provide a Good Economic Value in Colon Cancer Prevention? Value in Health. 17: A86-A87. DOI: 10.1016/J.Jval.2014.03.504 |
0.152 |
|
| 2015 |
Bajaj P, Willke R, Basu A, Sullivan S, Garrison L. When is Health Economics and outcomes research evidence important to U.S. payers? Value in Health. 18: A80. DOI: 10.1016/j.jval.2015.03.469 |
0.15 |
|
| 2021 |
Colson AR, Morton A, Årdal C, Chalkidou K, Davies SC, Garrison LP, Jit M, Laxminarayan R, Megiddo I, Morel C, Nonvignon J, Outterson K, Rex JH, Sarker AR, Sculpher M, et al. Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem? Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 24: 1828-1834. PMID 34838281 DOI: 10.1016/j.jval.2021.06.002 |
0.15 |
|
| 2022 |
Lee W, Wong WB, Kowal S, Garrison LP, Veenstra DL, Li M. Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. Pharmacoeconomics. PMID 35527331 DOI: 10.1007/s40273-022-01147-5 |
0.15 |
|
| 2021 |
Jiao B, Garrison LP. The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer. Expert Review of Pharmacoeconomics & Outcomes Research. 1-8. PMID 33645393 DOI: 10.1080/14737167.2021.1896968 |
0.15 |
|
| 2007 |
Best J, Garrison L, Hollingworth W, Ramsey S, Veenstra D. PR3 PREFERENCE VALUES FOR HEALTH STATES ASSOCIATED WITH COLON CANCER AND ITS TREATMENT Value in Health. 10: A16. DOI: 10.1016/S1098-3015(10)68580-4 |
0.148 |
|
| 2022 |
Xie J, Wang Y, Xu Y, Fine JT, Lam J, Garrison LP. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial. Journal of Medical Economics. 25: 51-58. PMID 34907813 DOI: 10.1080/13696998.2021.2011301 |
0.147 |
|
| 2015 |
Garrison LP, Carlson JJ, Bajaj PS, Towse A, Neumann PJ, Sullivan SD, Westrich K, Dubois RW. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. The American Journal of Managed Care. 21: 632-40. PMID 26618366 |
0.147 |
|
| 2022 |
Garrison LP, Hartgers-Gubbels ES, Chambers M. Value Insider Season 1 Episode 5: What Other Aspects of Value May Be Relevant? (Societal Impact) [Podcast]. International Journal of General Medicine. 15: 8217-8224. PMID 36451799 DOI: 10.2147/IJGM.S392906 |
0.147 |
|
| 2009 |
Carlson J, Sullivan S, Garrison L, Neumann P, Veenstra D. PHP64 LINKING PAYMENT AND HEALTH OUTCOMES: A SYSTEMATIC REVIEW AND TAXONOMY OF PERFORMANCE-BASED HEALTH OUTCOMES AGREEMENTS BETWEEN HEALTH CARE PAYERS AND MANUFACTURERS Value in Health. 12: A90. DOI: 10.1016/S1098-3015(10)73513-0 |
0.146 |
|
| 2021 |
Wong WB, To TM, Li M, Lee W, Veenstra DL, Garrison LP. Real-world evidence for option value in metastatic melanoma. Journal of Managed Care & Specialty Pharmacy. 1-10. PMID 34431715 DOI: 10.18553/jmcp.2021.21192 |
0.145 |
|
| 2007 |
Bresnahan B, Carlson R, Garrison L, Carpenter G, Neumann P, Sullivan S. PHP10 ASSESSING PAYER AND EMPLOYER PERSPECTIVES RELATED TO VALUE IN HEALTH CARE Value in Health. 10: A24-A25. DOI: 10.1016/S1098-3015(10)68607-X |
0.142 |
|
| 2013 |
Walzer S, Gartemann J, Zoellner Y, Towse A, Garrison L. Personalized Health Care in France, Germany and the United Kingdom: Are Health Technology Assessment Agencies Ready? Value in Health. 16: A475. DOI: 10.1016/j.jval.2013.08.882 |
0.142 |
|
| 2009 |
Veenstra D, Lin M, Garrison L, Burke W. PM4 AN EXPLORATION OF THE POTENTIAL CLINICAL BENEFITS AND RISKS OF CYP2D6 TESTING TO GUIDE TAMOXIFEN THERAPY IN BREAST CANCER Value in Health. 12: A4. DOI: 10.1016/S1098-3015(10)73083-7 |
0.142 |
|
| 2016 |
Mestre-Ferrandiz J, Garrison L, Zamora B. HEALTH TECHNOLOGY ASSESSMENT OF COMPLEMENTARY DIAGNOSTICS: ISSUES, OPTIONS, AND OPPORTUNITIES Value in Health. 19: A309. DOI: 10.1016/J.JVAL.2016.03.674 |
0.141 |
|
| 2021 |
Kleykamp BA, Dworkin RH, Turk DC, Bhagwagar Z, Cowan P, Eccleston C, Ellenberg SS, Evans SR, Gewandter JS, Goli V, Farrar JT, Freeman RL, Garrison LP, Iyengar S, Jadad AR, et al. Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT Recommendations. Pain. PMID 34510135 DOI: 10.1097/j.pain.0000000000002475 |
0.14 |
|
| 1984 |
Wills J, Garrison LP, Evens RG. The supply of and requirements for diagnostic and therapeutic radiologists Radiology. 151: 9-14. PMID 6701344 |
0.138 |
|
| 2021 |
Lee W, Li M, Wong WB, To TM, Garrison LP, Veenstra DL. Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 24: 1746-1753. PMID 34838272 DOI: 10.1016/j.jval.2021.07.004 |
0.136 |
|
| 2010 |
Bresnahan BW, Neumann PJ, Carlson R, Garrison LP, Sullivan SD. Findings related to assessing value for private US health plans American Journal of Pharmacy Benefits. 2: 219-228. |
0.13 |
|
| 2019 |
Garrison L, Towse A. PDG10 ALIGNING VALUE IN REGULATORY REVIEW, PRACTICE PATHWAYS, AND HEALTH TECHNOLOGY ASSESSMENT Value in Health. 22: S164. DOI: 10.1016/J.JVAL.2019.04.689 |
0.13 |
|
| 2021 |
Garrison LP, Schepman P, Bushmakin AG, Robinson RL, Tive L, Hall J, Dzingina M, Jackson J, Berry M, Cappelleri JC, Silverman S. Concern about addiction is associated with lower quality of life in patients with osteoarthritis: an exploratory, real-world data analysis. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. PMID 34219192 DOI: 10.1007/s11136-021-02907-0 |
0.128 |
|
| 2022 |
Li M, Garrison L, Lee W, Kowal S, Wong W, Veenstra D. A Pragmatic Guide to Assessing Real Option Value for Medical Technologies. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. PMID 35752536 DOI: 10.1016/j.jval.2022.05.014 |
0.127 |
|
| 2011 |
Garrison L, Best J, Robertson J, Wenten M, Bruhn D. PDB14 USING HEALTH OUTCOMES MODELING TO ASSESS THE BENEFIT-RISK PROFILE OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE-2 DIABETES Value in Health. 14: A93. DOI: 10.1016/j.jval.2011.02.522 |
0.127 |
|
| 2024 |
Shinkins B, Allen AJ, Karichu J, Garrison LP, Monz BU. Evidence Synthesis and Linkage for Modelling the Cost-Effectiveness of Diagnostic Tests: Preliminary Good Practice Recommendations. Applied Health Economics and Health Policy. PMID 38316713 DOI: 10.1007/s40258-023-00855-z |
0.12 |
|
| 2024 |
Li M, Garrison LP. Incorporating Real Option Value in Valuing Innovation: A Way Forward. Pharmacoeconomics. PMID 38310635 DOI: 10.1007/s40273-024-01352-4 |
0.12 |
|
| 2023 |
Garrison LP. Multicriteria Decision Analysis and Value Assessment Frameworks: Where Do We Stand? What Next? Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 27: 3-6. PMID 37918665 DOI: 10.1016/j.jval.2023.10.010 |
0.12 |
|
| 2007 |
Watkins J, Bresnahan B, Veenstra D, Garrison L, Sullivan S. PCASE12 DETERMINING THE VALUE OF DIAGNOSTIC/GENETIC TESTING TO INFORM HEALTH PLAN DECISION MAKING: ONCOTYPE DX AS A CASE STUDY Value in Health. 10: A206. DOI: 10.1016/S1098-3015(10)69152-8 |
0.118 |
|
| 2009 |
Goulart B, Sullivan S, Garrison L, Ramsey S, Martins R, Patrick D. PCN35 SYSTEMATIC REVIEW OF THE IMPACT OF CHEMOTHERAPY ON PATIENT REPORTED OUTCOMES IN ADVANCED NON-SMALL-CELL LUNG CANCER Value in Health. 12: A499. DOI: 10.1016/S1098-3015(10)75362-6 |
0.116 |
|
| 2011 |
Carlson J, Gries K, Sullivan S, Garrison L. PHP146 Current Status and Trends in Performance-Based Schemes Between Health Care Payers and Manufacturers Value in Health. 14: A359-A360. DOI: 10.1016/J.Jval.2011.08.696 |
0.11 |
|
| 2022 |
Jiao B, Nyame YA, Carlson JJ, Garrison LP, Basu A. Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 20: 1107-1115.e12. PMID 36240855 DOI: 10.6004/jnccn.2022.7044 |
0.109 |
|
| 2014 |
Watkins J, Sullivan S, Yeung K, Ramsey S, Garrison L, Wong E, Murphy C, Danielson D, Veenstra D, Vogeler C, Burke W, McGee R. Incentivizing Value In Managed Care Drug Formularies: Design, Implementation, And First-Year Outcomes Of A Value-Based Formulary Value in Health. 17: A6. DOI: 10.1016/j.jval.2014.03.042 |
0.107 |
|
| 2010 |
Thariani R, Carlson J, Wong W, Garrison L, Veenstra D, Ramsey S, Crowley J, Baker L, Barlow W, Burke W, Tunis S. PCN12 HORIZON SCANNING TO SUPPORT PRIORITY-SETTING FOR PROSPECTIVE COMPARATIVE EFFECTIVENESS RESEARCH (CER) IN CANCER GENOMICS Value in Health. 13: A25. DOI: 10.1016/S1098-3015(10)72103-3 |
0.105 |
|
| 2008 |
Fonnesbeck CJ, Garrison LP, Ward-Geiger LI, Baumstark RD. Bayesian hierarchichal model for evaluating the risk of vessel strikes on North Atlantic right whales in the SE United States Endangered Species Research. 6: 87-94. DOI: 10.3354/esr00134 |
0.104 |
|
| 2020 |
Incze A, Espin J, Kalo Z, Kiss E, Garrison L. PNS95 INTERNATIONAL REFERENCE PRICING: ACCEPTANCE AND AVOIDANCE BEHAVIORS AFFECTING PATIENT ACCESS AND INNOVATION IN U.S. AND BEYOND Value in Health. 23: S301. DOI: 10.1016/j.jval.2020.04.1098 |
0.103 |
|
| 2012 |
Nguyen H, Wang B, Garrison L. PHP97 Identifying Modeling Factors Influencing Coverage Decisions by Nice in 10 Single Technology Appraisals (STA) of Expensive Drugs Value in Health. 15: A625. DOI: 10.1016/j.jval.2012.08.141 |
0.102 |
|
| 1997 |
McGuire D, Garrison L, Armon C, Barohn RJ, Bryan WW, Miller R, Parry GJ, Petajan JH, Ross MA. A brief quality-of-life measure for ALS clinical trials based on a subset of items from the sickness impact profile. The Syntex-Synergen ALS/CNTF Study Group. Journal of the Neurological Sciences. 152: S18-22. PMID 9419049 DOI: 10.1016/S0022-510X(97)00239-6 |
0.1 |
|
| 2002 |
Hakim Z, Wolf A, Garrison LP. Estimating the effect of changes in body mass index on health state preferences. Pharmacoeconomics. 20: 393-404. PMID 12052098 |
0.098 |
|
| 2013 |
Slejko J, Garrison L, Willke R. Using Latent Class Probability Estimation And Residual Inclusion To Address Confounding In Medication Adherence Modeling Value in Health. 16: A7. DOI: 10.1016/j.jval.2013.03.042 |
0.098 |
|
| 2008 |
Carlson J, Garrison L, Ramsey S, Veenstra D. CN2 ECONOMIC EVALUATION OF EGFR-GUIDEDTREATMENT IN ADVANCED REFRACTORY NON SMALL-CELL LUNG CANCER Value in Health. 11: A10. DOI: 10.1016/S1098-3015(10)70045-0 |
0.096 |
|
| 2009 |
Veenstra D, Alfonso R, Best J, Bruhn D, Garrison L. PIH31 ASSESSING THE VALUE OF LESS FREQUENT MEDICATION DOSING ON ADHERENCE AND OUTCOMES Value in Health. 12: A167. DOI: 10.1016/S1098-3015(10)73899-7 |
0.095 |
|
| 1985 |
Garrison LP, Bowman MA, Perrin EB. Replies from the authors: Estimating physician requirements for neurology Neurology. 35: 1530. |
0.095 |
|
| 2013 |
Agapova M, Devine B, Bresnahan B, Garrison L. Quantification Of Benefits And Risks In Medical Imaging Testing: A Literature Review Value in Health. 16: A150. DOI: 10.1016/j.jval.2013.03.739 |
0.094 |
|
| 1985 |
Evans RW, Manninen DL, Garrison LP, Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG. The quality of life of patients with end-stage renal disease. The New England Journal of Medicine. 312: 553-9. PMID 3918267 DOI: 10.1056/NEJM198502283120905 |
0.092 |
|
| 2016 |
Cole A, Garrison L, Mestre-Ferrandiz J, Towse A. Data Governance For Real-World Evidence: Cross-Country Differences And Recommendations For A Governance Framework Value in Health. 19: A290-A291. DOI: 10.1016/j.jval.2016.03.745 |
0.091 |
|
| 2010 |
Wang B, Garrison L, Alfonso R, Flum D, Arteburn D, Sullivan S. PSY21 PROJECTING THE ECONOMIC OUTCOMES OF OBESITY USING A NATURAL HISTORY MODEL Value in Health. 13: A209. DOI: 10.1016/S1098-3015(10)73023-0 |
0.09 |
|
| 2016 |
Banerjee S, Roland C, Willke R, Mardekian J, Garrison L. (232) Prevalence of and comorbid health conditions associated with pediatric prescription opioid use in the US. The Journal of Pain : Official Journal of the American Pain Society. 17: S33-S34. PMID 28162462 DOI: 10.1016/J.Jpain.2016.01.136 |
0.088 |
|
| 2010 |
Veenstra D, Thariani R, Carlson J, Garrison L, Mohr P, Deverka P, Tunis S, Hoban C, Baker L, Ramsey S. PCN82 RESEARCH PRIORITIZATION FOR PROSPECTIVE COMPARATIVE EFFECTIVENESS RESEARCH (CER) IN CANCER GENOMICS Value in Health. 13: A266. DOI: 10.1016/S1098-3015(11)71977-5 |
0.087 |
|
| 2010 |
Veenstra DL, Garrison LP, Ramsey SD. Economic Issues and Genomic Medicine Essentials of Genomic and Personalized Medicine. 233-244. DOI: 10.1016/B978-0-12-374934-5.00020-9 |
0.083 |
|
| 2014 |
Rejon-Parrilla JC, Hernández-Villafuerte K, Shah K, Mestre-Ferrandiz J, Garrison L, Towse A. The Expanding Value Footprint of Oncology Treatments. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: A654. PMID 27202367 DOI: 10.1016/j.jval.2014.08.2386 |
0.081 |
|
| 2002 |
Link JS, Garrison LP, Almeida FP. Ecological interactions between elasmobranchs and groundfish species on the northeastern U.S. continental shelf. I. Evaluating predation North American Journal of Fisheries Management. 22: 550-562. DOI: 10.1577/1548-8675(2002)022<0550:EIBEAG>2.0.CO;2 |
0.078 |
|
| 2000 |
Garrison L, McDonnell ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. I65-9. PMID 10577976 DOI: 10.1136/ard.58.2008.i65 |
0.073 |
|
| 2003 |
Garrison LP. The ISPOR Good Practice Modeling Principles--a sensible approach: be transparent, be reasonable. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 6: 6-8. PMID 12535233 DOI: 10.1046/j.1524-4733.2003.00003.x |
0.071 |
|
| 2022 |
Garrison LP. Paying for Kidneys: Reflections on Welfare Economics, Political Economy, and Market Design. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 25: 1925-1928. PMID 36274005 DOI: 10.1016/j.jval.2022.09.005 |
0.067 |
|
| 2008 |
Baron SC, Martinez A, Garrison LP, Keith EO. Differences in acoustic signals from Delphinids in the western North Atlantic and northern Gulf of Mexico Marine Mammal Science. 24: 42-56. DOI: 10.1111/j.1748-7692.2007.00168.x |
0.066 |
|
| 2014 |
Litz JA, Baran MA, Bowen-Stevens SR, Carmichael RH, Colegrove KM, Garrison LP, Fire SE, Fougeres EM, Hardy R, Holmes S, Jones W, Mase-Guthrie BE, Odell DK, Rosel PE, Saliki JT, et al. Review of historical unusual mortality events (UMEs) in the Gulf of Mexico (1990-2009): providing context for the multi-year northern Gulf of Mexico cetacean UME declared in 2010. Diseases of Aquatic Organisms. 112: 161-75. PMID 25449327 DOI: 10.3354/Dao02807 |
0.062 |
|
| 2011 |
Wong E, Wang B, Garrison L, Alfonso-Cristancho R, Flum D, Arterburn D, Sullivan S. PSY78 ESTIMATING THE BMI-MORTALITY RELATION USING FRACTIONAL POLYNOMIALS Value in Health. 14: A73. DOI: 10.1016/j.jval.2011.02.410 |
0.062 |
|
| 2015 |
Hildebrand JA, Baumann-Pickering S, Frasier KE, Trickey JS, Merkens KP, Wiggins SM, McDonald MA, Garrison LP, Harris D, Marques TA, Thomas L. Passive acoustic monitoring of beaked whale densities in the Gulf of Mexico. Scientific Reports. 5: 16343. PMID 26559743 DOI: 10.1038/Srep16343 |
0.061 |
|
| 2016 |
Roberts JJ, Best BD, Mannocci L, Fujioka E, Halpin PN, Palka DL, Garrison LP, Mullin KD, Cole TV, Khan CB, McLellan WA, Pabst DA, Lockhart GG. Habitat-based cetacean density models for the U.S. Atlantic and Gulf of Mexico. Scientific Reports. 6: 22615. PMID 26936335 DOI: 10.1038/Srep22615 |
0.061 |
|
| 2014 |
Kim R, Kapur V, Garrison L, Ramsey S. An Economic Analysis Of Workplace Screening For Obstructive Sleep Apnea Value in Health. 17: A60. DOI: 10.1016/j.jval.2014.03.353 |
0.056 |
|
| 2011 |
Schick RS, Halpin PN, Read AJ, Urban DL, Best BD, Good CP, Roberts JJ, LaBrecque EA, Dunn C, Garrison LP, Hyrenbach KD, McLellan WA, Pabst DA, Palka DL, Stevick P. Community structure in pelagic marine mammals at large spatial scales Marine Ecology Progress Series. 434: 165-181. DOI: 10.3354/Meps09183 |
0.055 |
|
| 2008 |
Campbell J, Veenstra D, Garrison L, Sullivan S. PRS45 THE DEVELOPMENT AND VALIDATION OF A CONTEMPORARY ASTHMA POLICY MODEL Value in Health. 11: A283. DOI: 10.1016/S1098-3015(10)70893-7 |
0.054 |
|
| 2002 |
Link JS, Garrison LP. Trophic ecology of Atlantic cod Gadus morhua on the northeast US continental shelf Marine Ecology Progress Series. 227: 109-123. |
0.052 |
|
| 2000 |
Garrison LP, Link JS. Dietary guild structure of the fish community in the Northeast United States continental shelf ecosystem Marine Ecology Progress Series. 202: 231-240. |
0.052 |
|
| 2007 |
Garrison LP. Interactions between marine mammals and pelagic longline fishing gear in the U.S. Atlantic Ocean between 1992 and 2004 Fishery Bulletin. 105: 408-417. |
0.051 |
|
| 2000 |
Garrison LP, Link JS. Diets of five hake species in the northeast United States continental shelf ecosystem Marine Ecology Progress Series. 204: 243-255. |
0.051 |
|
| 2012 |
Tsang K, Wang B, Garrison L. PRM34 Estimating Markov Chain Transition Matrices in Limited Data Samples: A Monte Carlo Experiment Value in Health. 15: A164-A165. DOI: 10.1016/j.jval.2012.03.890 |
0.05 |
|
| 2016 |
Chen Y, Wang B, Furnback W, Garrison L, Dong P, Xie G, Guzauskas G, Gu C. Precision Heor: Using Big Data to Develop a Personalized Modeling Framework Value in Health. 19: A853. DOI: 10.1016/j.jval.2016.08.467 |
0.05 |
|
| 2007 |
Litz JA, Garrison LP, Fieber LA, Martinez A, Contillo JP, Kucklick JR. Fine-scale spatial variation of persistent organic pollutants in bottlenose dolphins (Tursiops truncatus) in Biscayne Bay, Florida. Environmental Science & Technology. 41: 7222-8. PMID 18044492 DOI: 10.1021/Es070440R |
0.049 |
|
| 1999 |
Garrison LP, Morgan JA. Abundance and vertical distribution of drifting, post-larval Macoma spp. (Bivalvia: Tellinidae) in the York River, Virginia, USA Marine Ecology Progress Series. 182: 175-185. |
0.041 |
|
| 1983 |
Evans RW, Manninen DL, Garrison LP, Hart LG. The use of rehabilitation services by patients with chronic renal failure: results from the National Kidney Dialysis and Kidney Transplantation Study Aannt Journal / the American Association of Nephrology Nurses and Technicians. 10: 19-25. PMID 6360186 |
0.04 |
|
| 2002 |
Link JS, Garrison LP. Changes in piscivory associated with fishing induced changes to the finfish community on Georges Bank Fisheries Research. 55: 71-86. DOI: 10.1016/S0165-7836(01)00300-9 |
0.04 |
|
| 1999 |
Garrison LP. Vertical migration behavior and larval transport in brachyuran crabs Marine Ecology Progress Series. 176: 103-113. |
0.037 |
|
| 2022 |
Xie RZ, Towse A, Garrison LP. Should We Pay for Scientific Knowledge Spillovers?: The Underappreciated Value of "Failed" R&D Efforts. International Journal of Technology Assessment in Health Care. 1-17. PMID 35297363 DOI: 10.1017/S0266462322000150 |
0.037 |
|
| 2000 |
Garrison LP. Spatial and dietary overlap in the Georges Bank groundfish community Canadian Journal of Fisheries and Aquatic Sciences. 57: 1679-1691. |
0.036 |
|
| 2000 |
Garrison LP, Link JS. Fishing effects on spatial distribution and trophic guild structure of the fish community in the Georges Bank region Ices Journal of Marine Science. 57: 723-730. DOI: 10.1006/jmsc.2000.0713 |
0.03 |
|
| 2012 |
Best BD, Halpin PN, Read AJ, Fujioka E, Good CP, LaBrecque EA, Schick RS, Roberts JJ, Hazen LJ, Qian SS, Palka DL, Garrison LP, McLellan WA. Online cetacean habitat modeling system for the US East Coast and Gulf of Mexico Endangered Species Research. 18: 1-15. DOI: 10.3354/Esr00430 |
0.028 |
|
| 2000 |
Garrison LP, Michaels W, Link JS, Fogarty MJ. Predation risk on larval gadids by pelagic fish in the Georges Bank ecosystem. I. Spatial overlap associated with hydrographic features Canadian Journal of Fisheries and Aquatic Sciences. 57: 2455-2469. DOI: 10.1139/cjfas-57-12-2455 |
0.027 |
|
| 2010 |
Garrison LP, Link JS, Kilduff DP, Cieri MD, Muffley B, Vaughan DS, Sharov A, Mahmoudi B, Latour RJ. An expansion of the MSVPA approach for quantifying predator-prey interactions in exploited fish communities Ices Journal of Marine Science. 67: 856-870. DOI: 10.1093/icesjms/fsq005 |
0.025 |
|
| 2002 |
Garrison LP, Michaels W, Link JS, Fogarty MJ. Spatial distribution and overlap between ichthyoplankton and pelagic fish and squids on the southern flank of Georges Bank Fisheries Oceanography. 11: 267-285. DOI: 10.1046/j.1365-2419.2002.00205.x |
0.023 |
|
| 2014 |
Soldevilla MS, Rice AN, Clark CW, Garrison LP. Passive acoustic monitoring on the North Atlantic right whale calving grounds Endangered Species Research. 25: 115-140. DOI: 10.3354/Esr00603 |
0.018 |
|
| 2012 |
Litz JA, Hughes CR, Garrison LP, Fieber LA, Rosel PE. Genetic structure of common bottlenose dolphins (Tursiops truncatus) inhabiting adjacent South Florida estuaries - Biscayne Bay and Florida Bay Journal of Cetacean Research and Management. 12: 107-117. |
0.016 |
|
| 2010 |
Garrison LP, Martinez A, Maze-Foley K. Habitat and abundance of cetaceans in Atlantic Ocean continental slope waters off the eastern USA Journal of Cetacean Research and Management. 11: 267-277. |
0.01 |
|
| 1888 |
ANDERSON W, ARMSTRONG HE, BARRETT WF, EWING JA, GARRISON L, GREENWOOD WH, HALL JF, POURCEL A, THWAITE BM, HADFIELD RA. CORRESPONDENCE. MANGANESE STEEL. Minutes of the Proceedings of the Institution of Civil Engineers. 93: 108-126. DOI: 10.1680/imotp.1888.21058 |
0.01 |
|
| Hide low-probability matches. |